Haemonetics Corporation
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information tech… Read more
Market Cap & Net Worth: Haemonetics Corporation (HAE)
Haemonetics Corporation (NYSE:HAE) has a market capitalization of $2.77 Billion ($2.77 Billion) as of March 18, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #4330 globally and #2718 in its home market, demonstrating a -6.91% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Haemonetics Corporation's stock price $59.70 by its total outstanding shares 46471350 (46.47 Million).
Haemonetics Corporation Market Cap History: 2015 to 2026
Haemonetics Corporation's market capitalization history from 2015 to 2026. Data shows growth from $1.50 Billion to $2.77 Billion (6.11% CAGR).
Index Memberships
Haemonetics Corporation is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
S&P Midcap 400
MID
|
$3.04 Trillion | 0.12% | #355 of 401 |
Weight: Haemonetics Corporation's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Haemonetics Corporation Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Haemonetics Corporation's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.74x
Haemonetics Corporation's market cap is 2.74 times its annual revenue
0.67x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
22.21x
Haemonetics Corporation's market cap is 22.21 times its annual earnings
1.97x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.87 Billion | $908.83 Million | -$55.62 Million | 2.06x | N/A |
| 2017 | $2.70 Billion | $886.12 Million | -$26.27 Million | 3.05x | N/A |
| 2018 | $4.65 Billion | $903.92 Million | $45.57 Million | 5.14x | 102.02x |
| 2019 | $5.34 Billion | $967.58 Million | $55.02 Million | 5.52x | 97.05x |
| 2020 | $5.52 Billion | $988.48 Million | $76.53 Million | 5.58x | 72.11x |
| 2021 | $2.46 Billion | $870.46 Million | $79.47 Million | 2.83x | 31.02x |
| 2022 | $3.65 Billion | $993.20 Million | $43.38 Million | 3.68x | 84.26x |
| 2023 | $3.97 Billion | $1.17 Billion | $115.40 Million | 3.40x | 34.43x |
| 2024 | $3.63 Billion | $1.31 Billion | $117.56 Million | 2.77x | 30.87x |
| 2025 | $3.72 Billion | $1.36 Billion | $167.68 Million | 2.74x | 22.21x |
Competitor Companies of HAE by Market Capitalization
Companies near Haemonetics Corporation in the global market cap rankings as of March 18, 2026.
Key companies related to Haemonetics Corporation by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #79 globally with a market cap of $190.05 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #153 globally with a market cap of $121.18 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #169 globally with a market cap of $112.92 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #191 globally with a market cap of $103.18 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #79 | Abbott Laboratories | NYSE:ABT | $190.05 Billion | $109.95 |
| #153 | Stryker Corporation | NYSE:SYK | $121.18 Billion | $349.56 |
| #169 | Medtronic PLC | NYSE:MDT | $112.92 Billion | $88.24 |
| #191 | Boston Scientific Corp | NYSE:BSX | $103.18 Billion | $69.79 |
Haemonetics Corporation Historical Marketcap From 2015 to 2026
Between 2015 and today, Haemonetics Corporation's market cap moved from $1.50 Billion to $ 2.77 Billion, with a yearly change of 6.11%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.77 Billion | -25.51% |
| 2025 | $3.72 Billion | +2.65% |
| 2024 | $3.63 Billion | -8.69% |
| 2023 | $3.97 Billion | +8.72% |
| 2022 | $3.65 Billion | +48.28% |
| 2021 | $2.46 Billion | -55.33% |
| 2020 | $5.52 Billion | +3.35% |
| 2019 | $5.34 Billion | +14.84% |
| 2018 | $4.65 Billion | +72.26% |
| 2017 | $2.70 Billion | +44.48% |
| 2016 | $1.87 Billion | +24.69% |
| 2015 | $1.50 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Haemonetics Corporation was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.77 Billion USD |
| MoneyControl | $2.77 Billion USD |
| MarketWatch | $2.77 Billion USD |
| marketcap.company | $2.77 Billion USD |
| Reuters | $2.77 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.